<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:chebi fb="1" ids="17650">cortisol</z:chebi>-regenerating enzyme 11β-<z:chebi fb="0" ids="35350">hydroxysteroid</z:chebi> dehydrogenase type 1 (11β-HSD1) amplifies <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> levels in liver and adipose tissue </plain></SENT>
<SENT sid="1" pm="."><plain>11β-HSD1 inhibitors are being developed to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0001513'>obesity</z:hpo>, 11β-HSD1 is increased in adipose tissue but decreased in liver </plain></SENT>
<SENT sid="3" pm="."><plain>The benefits of pharmacological inhibition may be reduced if hepatic 11β-HSD1 is similarly decreased in <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>To examine this, we quantified in vivo whole-body, splanchnic, and hepatic 11β-HSD1 activity in <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic subjects </plain></SENT>
<SENT sid="5" pm="."><plain>RESEARCH DESIGN AND METHODS: Ten <z:mp ids='MP_0001261'>obese</z:mp> men with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and seven <z:mpath ids='MPATH_458'>normal</z:mpath>-weight control subjects were infused with 9,11,12,12-[(2)H](4)<z:chebi fb="1" ids="17650">cortisol</z:chebi> (40%) and <z:chebi fb="1" ids="17650">cortisol</z:chebi> (60%) at 1.74 mg/h </plain></SENT>
<SENT sid="6" pm="."><plain>Adrenal <z:chebi fb="1" ids="17650">cortisol</z:chebi> secretion was suppressed with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Samples were obtained from the hepatic vein and an arterialized hand vein at steady state and after oral administration of <z:chebi fb="11" ids="16962">cortisone</z:chebi> (5 mg) to estimate whole-body and liver 11β-HSD1 activity using tracer dilution </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic subjects, the appearance rate of 9,12,12-[(2)H](3)<z:chebi fb="1" ids="17650">cortisol</z:chebi> in arterialized blood was increased (35 ± 2 vs. 29 ± 1 nmol/min, P &lt; 0.05), splanchnic 9,12,12-[(2)H](3)<z:chebi fb="1" ids="17650">cortisol</z:chebi> production was not reduced (29 ± 6 vs. 29 ± 6 nmol/min), and <z:chebi fb="1" ids="17650">cortisol</z:chebi> appearance in the hepatic vein after oral <z:chebi fb="11" ids="16962">cortisone</z:chebi> was unchanged </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Whole-body 11β-HSD1 activity is increased in <z:mp ids='MP_0001261'>obese</z:mp> men with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, whereas liver 11β-HSD1 activity is sustained, unlike in euglycemic <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>This supports the concept that inhibitors of 11β-HSD1 are likely to be most effective in <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic subjects </plain></SENT>
</text></document>